Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | PTPN7 | P35236 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10430342 | 1.00 | KMT2A (1.00) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL10430343 | 1.00 | KMT2A (1.00) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL525255 | 0.84 | KMT2A (0.72) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL15388844 | 0.82 | KMT2A (0.69) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL27495771 | 0.80 | KMT2A (0.67) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL27391080 | 0.80 | KMT2A (0.67) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL5319337 | 0.80 | KMT2A (0.67) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL29241351 | 0.79 | KMT2A (0.66) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL9318301 | 0.79 | KMT2A (0.65) | KMT2APOLBPTPN1L3MBTL1PKM | |
| SCHEMBL4753938 | 0.79 | KMT2A (0.65) | KMT2APOLBPTPN1L3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118967-A | Preparation method of 2-furanone acid | 重庆新征程生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2009083551-A1 | PROCESS FOR PREPARING CARBOXYLIC ESTERS | BIOREFINERY.DE GMBH (DE) | 2009-07-09 | — | — | WO | claimed |
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2009-04-23 | — | — | US | claimed |
| US-6740731-B2 | COMPRISING A HYDROXYCARBOXYLIC ACID-CONTAINING POLYMER WHERE THE POLYMER BIODEGRADES HYDROLYTICALLY DURING STORAGE, USE AND DISPOSAL STAGES IN A CONTROLLED MANNER,THE RATE BEING ACCELERATED DURING DISPOSAL; MICROBIOCIDES | CARGILL DOW POLYMERS LLC | 2004-05-25 | — | — | US | claimed |
| US-20020123546-A1 | Degradation control of environmentally degradable disposable materials | ECOPOL, LLC | 2002-09-05 | — | — | US | claimed |
| EP-0722433-B1 | METHOD TO PRODUCE CYCLIC ESTERS | BIOPAK TECHNOLOGY LTD (US) | 2000-01-26 | — | — | EP | claimed |
| JP-2922303-B2 | — | — | 1999-07-19 | — | — | JP | claimed |
| EP-0632807-B1 | PROCESS FOR THE PRODUCTION OF CYCLIC ESTERS FROM HYDROXY ACIDS AND DERIVATIVES THEREOF | BIOPAK TECHNOLOGY LTD (US) | 1998-08-19 | — | — | EP | claimed |
| CN-1186491-A | Method to produce and purity cyclic esters | CHRONOPOL INC (US) | 1998-07-01 | — | — | CN | claimed |
| EP-0830358-A1 | METHOD TO PRODUCE AND PURIFY CYCLIC ESTERS | Chronopol, Inc. (US) | 1998-03-25 | — | — | EP | claimed |
| EP-0662107-A4 | DEGRADATION CONTROL OF ENVIRONMENTALLY DEGRADABLE DISPOSABLE MATERIALS. | BIOPAK TECHNOLOGY LTD (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0662107-A1 | DEGRADATION CONTROL OF ENVIRONMENTALLY DEGRADABLE DISPOSABLE MATERIALS | BioPak Technology, Ltd. (US) | 1995-07-12 | — | — | EP | claimed |
| US-5420304-A | Esterification and cyclization then solvent extraction | BIOPAK TECHNOLOGY, LTD. (US) | 1995-05-30 | — | — | US | claimed |
| EP-0632807-A4 | PROCESS FOR THE PRODUCTION OF CYCLIC ESTERS FROM HYDROXY ACIDS AND DERIVATIVES THEREOF. | BIOPAK TECHNOLOGY LTD (US) | 1995-05-03 | — | — | EP | claimed |
| WO-1995009142-A1 | METHOD TO PRODUCE CYCLIC ESTERS | BIOPAK TECHNOLOGY, LTD. (US) | 1995-04-06 | — | — | WO | claimed |
| EP-0632807-A1 | PROCESS FOR THE PRODUCTION OF CYCLIC ESTERS FROM HYDROXY ACIDS AND DERIVATIVES THEREOF | BIOPAK TECHNOLOGY LTD (US) | 1995-01-11 | — | — | EP | claimed |
| US-5319107-A | By direct dehydration of hydroxy carboxylic acids or derivatives; lactide, glycolide | BIOPAK TECHNOLOGY, LTD. (US) | 1994-06-07 | — | — | US | claimed |
| WO-1994006866-A1 | DEGRADATION CONTROL OF ENVIRONMENTALLY DEGRADABLE DISPOSABLE MATERIALS | BIOPAK TECHNOLOGY, LTD. (US) | 1994-03-31 | — | — | WO | claimed |
| CN-1080921-A | The method for preparing cyclic ester with hydroxy acid and derivative thereof | BIOPAK TECHNOLOGY LTD (US) | 1994-01-19 | — | — | CN | claimed |
| WO-1993019058-A2 | PROCESS FOR THE PRODUCTION OF CYCLIC ESTERS FROM HYDROXY ACIDS AND DERIVATIVES THEREOF | BIOPAK TECHNOLOGY LTD. (US) | 1993-09-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105240-A1 | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same | MCL1, AS3MT, MYADM | KMT2A 848/4885POLB 819/4885PTPN1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.